EU Approves Pfizer's Hympavzi as First Weekly Subcutaneous Treatment for Severe Hemophilia B
核心洞察
The European Commission has approved Pfizer's Hympavzi, a once-weekly subcutaneous treatment, for severe hemophilia B (搜索) in adults and adolescents without inhibitors.
Hympavzi is the first anti-TFPI (搜索) antibody approved in Europe for hemophilia A (搜索) or B without inhibitors, offering convenient at-home administration via autoinjector.
The approval was based on the Phase 3 BASIS study, which demonstrated a 35% reduction in annualized bleeding rate compared to routine clotting factor injections.
Pfizer's Hympavzi (marstacimab) has received approval from the European Commission as the first once-weekly subcutaneous treatment for individuals with severe hemophilia B (搜索). This approval extends to adults and adolescents aged 12 and older who do not have inhibitors. Hympavzi distinguishes itself as the first in its class in Europe, offering a novel approach to managing this challenging condition. The drug's approval follows its recent green light in the United States.
Clinical Significance
According to Dr. Laurent Frenzel, a hemophilia specialist at the Necker-Enfants Malades Hospital in Paris, "There is a considerable treatment burden associated with the standard-of-care options for hemophilia A (搜索) and B, including time-consuming preparation and administration of infusions and injections potentially causing missed doses and an increased risk of bleeding." Hympavzi addresses this burden by offering a convenient, once-weekly subcutaneous administration via a pre-filled pen, potentially improving patient adherence and quality of life.
BASIS Phase 3 Trial Results
The approval is supported by data from the Phase 3 BASIS study, which demonstrated a significant reduction in the annualized bleeding rate (ABR) with Hympavzi. Specifically, the study showed a 35% reduction in ABR for treated bleeds over a 12-month treatment period compared to routine injections of recombinant clotting factors. The most common side effects, affecting less than 3% of patients, included injection site reactions, headache, and itching.
Mechanism of Action and Dosing
Hympavzi functions as an anti-TFPI (搜索) antibody. Notably, the drug can be administered as a flat dose, independent of the patient's weight, which simplifies the administration process.
Competitive Landscape
Hympavzi enters a competitive market that includes Roche's Hemlibra (emicizumab) for hemophilia A (搜索), which boasts less frequent dosing and approval for patients with and without inhibitors. Sanofi's Altuviiio (efanesoctocog alfa), a long-acting Factor VIII replacement therapy with once-weekly dosing, is another competitor. However, analysts suggest that Hympavzi's greatest opportunity lies in hemophilia B (搜索), where it offers a significant advancement over standard clotting factor replacement therapies that require multiple weekly administrations.
Novo Nordisk's concizumab, a similar TFPI (搜索) inhibitor, faced rejection by the FDA due to manufacturing issues but has been launched in Canada, Japan, Australia, and Switzerland as Alhemo. It received a positive recommendation for EU approval from the EMA. Alhemo is indicated for hemophilia A (搜索) and B patients with inhibitors, differentiating it from Hympavzi's current indication.